Green Chemistry in the Pharmaceutical Industry
(Sprache: Englisch)
Packed with brand-new information, including several industrial case studies
Green Chemistry in the Pharmaceutical Industry is a multidisciplinary endeavour, requiring contributions from chemists, chemical engineers and molecular biologists.
Jetzt vorbestellen
versandkostenfrei
Buch (Gebunden)
166.60 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Green Chemistry in the Pharmaceutical Industry “
Packed with brand-new information, including several industrial case studies
Green Chemistry in the Pharmaceutical Industry is a multidisciplinary endeavour, requiring contributions from chemists, chemical engineers and molecular biologists.
Klappentext zu „Green Chemistry in the Pharmaceutical Industry “
Edited by three of the world s leading pharmaceutical scientists, this is the first book on this important and hot topic, containing much previously unpublished information. As such, it covers all aspects of green chemistry in the pharmaceutical industry, from simple molecules to complex proteins, and from drug discovery to the fate of pharmaceuticals in the environment. Furthermore, this ready reference contains several convincing case studies from industry, such as Taxol, Pregabalin and Crestor, illustrating how this multidisciplinary approach has yielded efficient and environmentally-friendly processes. Finally, a section on technology and tools highlights the advantages of green chemistry.
Inhaltsverzeichnis zu „Green Chemistry in the Pharmaceutical Industry “
INTRODUCTION TO GREEN CHEMISTRY, ORGANIC SYNTHESIS AND PHARMACEUTICALSThe Development of Organic SynthesisThe Environmental FactorThe Role of CatalysisGreen Chemistry: Benign by DesignIbuprofen ManufactureThe Question of Solvents: Alternative Reaction MediaBiocatalysis: Green Chemistry Meets White BiotechnologyConclusions and ProspectsGREEN CHEMISTRY METRICSIntroductionMeasuring Resource UsageLife Cycle Assessment (LCA)Measuring Chemistry and Process EfficiencyMeasuring Process Parameters and EmissionsReal Time AnalysisOperational EfficiencyMeasuring EnergyMeasuring the Toxicity of All the SubstratesMeasuring Degradation PotentialMeasuring the Inherent Safety of Lack of Inherent SafetyConclusionsSOLVENT USE AND WASTE ISSUESIntroduction to Solvent Use and Waste IssuesSolvent and Process Greenness Scoring and Selection ToolsWaste Minimization and Solvent RecoveryENVIRONMENTAL AND REGULATORY ASPECTSHistorical PerspectivePharmaceuticals in the EnvironmentEnvironmental RegulationsA Look to the FutureSYNTHESIS OF SITAGLIPTIN, THE ACTIVE INGREDIENT IN JANUVIA AND JANUMETIntroductionFirst-Generation RouteSitagliptin through Diastereoselective Hydrogenation of an Enamine. The PGA Enamine-Ester RouteThe Triazole FragmentDirect Preparation of Beta-Keto AmidesSecond-Generation Chiral Auxiliary Route. The PGA Enamine-Amide RoutePrufication and Isolation of Sitagliptin (Pharmaceutical Form)The Final Manufacturing RouteTHE DEVELOPMENT OF SHORT, EFFICIENT, ECONOMIC, AND SUSTAINABLE CHEMOENZYMATIC PROCESSES FOR STATIN SIDE CHAINSIntroduction: BiocatalysisThe Relevance of StatinsBiocatalytic Routes to Statin Side Chains2-Deoxy-D-Ribose 5-Phosphate Aldolase (DERA)-Based Routes to Statin IntermediatesConclusionsTHE TAXOL STORY-DEVELOPMENT OF A GREEN SYNTHESIS VIA PLANT CELL FERMENTATIONIntroductionDiscovery and Early DevelopmentFrom Extraction of Taxol from Pacific Yew Tree Bark to Semi-Synthetic TaxolTaxol from Plant Cell FermentationComparison of Semi-Synthetic versus PCF Taxol
... mehr
Processes: The Environmental ImpactComparison of Semi-Synthetic versus PCF Taxol: Green Chemistry PrinciplesFinal WordsTHE DEVELOPMENT OF A GREEN, ENERGY EFFICIENT, CHEMOENZYMATIC MANUFACTURING PROCESS OF PREGABALINIntroductionProcess Routes to PregabalinBiocatalytic Route to PregabalinGreen Chemistry ConsiderationsConclusionsGREEN PROCESSES FOR PEPTIDE MIMETIC DIABETIC DRUGSIntroductionGreen Chemistry Considerations in Peptide-like API manufacturePurification Process to Manufacture Amorphous APIPreparation of Unnatural Amino AcidsSummaryTHE DEVELOPMENT OF AN ENVIRONMENTALLY SUSTAINABLE PROCESS FOR RADAFAXINEIntroductionChemistry Process and the Dynamic Kinetic Resolution (DKR)Multicolumn Chromatography - Development of Route 4Environmental AssessmentSummaryCONTINUOUS PROCESSING IN THE PHARMACEUTICAL INDUSTRYIntroductionContinuous Production of a Key Intermediate for AtorvastatinContinuous Process to Prepare CelecoxibContinuous Oxidation of Alcohols to AldehydesContinuous Production of BromonitromethaneContinuous Production and Use of DiazomehtaneA Snapshot of Some Further Continuous Processes Used in the Preparation of Pharmaceutical AgentsConclusionsPREPARATIVE AND INDUSTRIAL SCALE CHROMATOGRAPHY: GREEN AND INTEGRATED PROCESSESIntroductionBasic Principles of ChromatographyProcess Optimization to Reduce Eluent ConsumptionUse of a Green Solvent: Supercritical Carbon DioxideSolvent Recycling TechnologiesApplication ExamplesConclusion: An Environmentally Friendly Solution for Each SeparationDYNAMIC RESOLUTION OF CHIRAL AMINE PHARMACEUTICALS: TURNING WASTE ISOMERS INTO USEFUL PRODUCTBackgroundIntegration of Chiral Amine Resolution and RacemizationCase StudiesConclusionsGREEN TECHNOLOGIES IN THE GENERIC PHARMACEUTICAL INDUSTRYIntroduction'Waste': Definition and RemedyAmidationSynthesis of GalanthamineSynthesis of SolefinacinSynthesis of LevetiracetamSynthesis of a Finasteride IntermediateBrominationSulfoxidation in the Synthesis of RabeprazoleConclusionsENVIRONMENTAL CONSIDERATIONS IN BIOLOGICS MANUFACTUREIntroductionTherapeutic BiologicsEnvironmental Impact ConsiderationsOverall ComparisonEnvironmental Indices for Therapeutic Protein ManufactureTechnologies with Potential Environmental ImpactSingle-Use Biologics ManufactureSummaryFUTURE TRENDS FOR GREEN CHEMISTRY IN THE PHARMACEUTICAL INDUSTRYIntroductionWaste Minimization in Drug DiscoveryGreener Synthetic Methods in Primary ManufacturingAlternative Solvents in the Pharmaceutical IndustryGreen Chemistry in Secondary Pharmaceutical OperationsGlobal Cooperation in Green ChemistryConclusions
... weniger
Autoren-Porträt von Joseph D. Armstrong, Jaume Balsells, Rakeshwar Bandichhor, Apurba Bhattacharya, John Blacker, Jean Bléhaut
Peter Dunn received his PhD from Imperial College London in 1987 working under the supervision of Professor Charles Rees. Postdoctoral work followed with Prof. Albert Eschenmoser at the ETH, Zurich and with Prof. Henry Rapaport at the University of California, Berkeley. In 1989 he joined Pfizer and was involved with the invention of the commercial processes to make several medicines including "Viagra", Emselex, Revation and Sampatrilat. In 2000 he became Director of Chemical R & D at Pfizer and was responsible for the filing and transfer to manufacturing of human and animal medicines such as Voriconazole, Darifenacin, Fosfluconazole and Dirlotapide. In 2006 he took up his current role as Global Green Chemistry lead for Pfizer. He is currently co-chair of the Green Chemistry Institute Pharmaceutical Roundtable and a member of the editorial board for the journal of Green Chemistry.Andrew Wells obtained his PhD in organophosphorous and organometallic chemistry from Essex University, before joining the Chemical Development Group of SmithKline & French in 1986, which later became SmithKline Beecham. In 1999 he received a SKB corporate award for green chemistry/technology. In 2000, he joined AstraZeneca in Global Process R & D where he is currently a Senior Principal Scientist and heads the AZ GPRD Green Chemistry group. He is an active member of the ACS Green Chemistry Institute Pharmaceutical Roundtable and has acted as an advisor to the UK Chemical Innovation Knowledge Transfer Network and the UK Technology Strategy Board. A keen supporter of the industry-academia interface, having been involved closely with several major collaborations such as the Centre for Biocatalysis at Manchester and the Institute of Process R & D at Leeds University, he has also been an industrial supervisor to around 20 PhD and MSc students.Michael Williams obtained his chemistry BSc from King's College, London, and spent time as a medicinal chemist at ICI Pharmaceuticals
... mehr
(Alderley Park), before obtaining his PhD working with Professor Charles Rees at the University of Liverpool. He joined the Chemical R & D department at Pfizer at Sandwich in 1972, where his career responsibilities included the Medicinal Chemistry/Development interface, and technology adoption. In addition to his experience with approximately 50 early drug candidates, he played a significant role in the late development, filing and commercializing of many agents including Zoloft, Viagra and Relpax. He became Executive Director and Departmental Head of UK Chemical R & D in 2003, leading a significant growth to 117 laboratory staff, and helping to build a 40 strong Material Sciences group. Since retiring from Pfizer in 2007, he has been an independent consultant, in addition to his work in editing and scientific writing.
... weniger
Bibliographische Angaben
- Autoren: Joseph D. Armstrong , Jaume Balsells , Rakeshwar Bandichhor , Apurba Bhattacharya , John Blacker , Jean Bléhaut
- 2010, XVIII, 370 Seiten, 18 farbige Abbildungen, 169 Schwarz-Weiß-Abbildungen, Maße: 17,9 x 24,6 cm, Gebunden, Englisch
- Herausgegeben: Peter J. Dunn, Andrew S. Wells, Michael T. Williams
- Verlag: Wiley-VCH
- ISBN-10: 3527324186
- ISBN-13: 9783527324187
- Erscheinungsdatum: 10.03.2010
Sprache:
Englisch
Rezension zu „Green Chemistry in the Pharmaceutical Industry “
"At last! A book which looks at Green Chemistry from an industrial viewpoint! This is the best book I have read on Green Chemistry and should be on the bookshelf of every process chemist and engineer. Outstanding!" ( Organic Process Research & Development , March 2010)
Pressezitat
"At last! A book which looks at Green Chemistry from an industrial viewpoint! This is the best book I have read on Green Chemistry and should be on the bookshelf of every process chemist and engineer. Outstanding!" ( Organic Process Research & Development , March 2010)
Kommentar zu "Green Chemistry in the Pharmaceutical Industry"
Schreiben Sie einen Kommentar zu "Green Chemistry in the Pharmaceutical Industry".
Kommentar verfassen